Year | Method | Samples number | Chosen markers of NETs | Type of Cancer | Function | Reference |
---|---|---|---|---|---|---|
2016 | ELISA | 35 | MPO-DNA complex | Colorectal cancer | correlated with the reduction in DFS | [42] |
2018 | ELISA | 161 | Citrullinated histone H3 | Pan-cancer | prognostic blood marker | [109] |
2019 | ELISA | 45 | NE-DNA complex | Breast cancer | associated with clinical stages | [117] |
2019 | ELISA | 27 | MPO-DNA complex | Colorectal cancer | correlated with shorter survival | [41] |
2019 | ELISA | 104 | MPO-DNA complex | Pancreatic ductal adenocarcinoma | related to the clinical stage | [19] |
2019 | ELISA | 957 | Citrullinated histone H3 | Pan-cancer | associated with higher mortality | [110] |
2019 | IHC | 317 | Citrullinated histone H3 | Pancreatic ductal adenocarcinoma | prognostic factor | [113] |
2019 | ELISA | 138 | circulating DNA | Pan-cancer | related to cancer-related stroke | [114] |
2019 | ELISA | 75 | MPO-DNA complex | Esophagogastric and lung adenocarcinoma | correlated with advanced stage | [106] |
2020 | ELISA | 356 | NE-DNA complex | Gastric Adenocarcinoma | diagnostic, therapeutic predictive, and prognostic value | [108] |
2020 | ELISA | 461 | MPO-DNA complex | Breast cancer | metastases predictor | [11] |
2022 | IHC | 321 | MPO | Pan-cancer | prognostic factor | [13] |
2022 | ELISA | 25 | MPO-DNA complex | Breast cancer | monitoring HER2 antibody–drug-associated vasculitis activity | [116] |